Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Liaoning Tumor Hospital & Institute

Status: Completed

Conditions: HER2-positive Metastatic Breast Cancer

Treatments: Drug: inetetamab

Study type: Observational

Funder types: Other

Identifiers

NCT06305702

LZRXN-001

Details and patient eligibility

About

A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.

Enrollment: 500 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. An age of at least 18 years or older
2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer
3. Having at least one measurable lesion as defined
4. Receiving inetetamab-based therapy in the recurrent or metastatic stage
5. Having traceable medical history records

Exclusion criteria

1. Pregnant or lactating women
2. Patients with other conditions deemed unsuitable for participating in this study by the researcher